Putting the Research back into CRO
Because the right technical route isn’t always predefined —
and the workflow shouldn’t be either.
A research led approach to outsourcing
Research rarely starts with every answer already defined. A university group exploring a new biomarker, a spin-out translating an idea into a viable product or an emerging biotech developing a new reagent or assay may know what they want to achieve without yet knowing the optimum technical route.
Yet outsourcing models built around standardised platforms, established workflows and go-to techniques do not always leave much room for that uncertainty. For research stage programmes, the ability to compare options, adapt the approach and follow the data can be just as important as the ability to execute a process.
Other clients may be further along, bringing a preferred chemistry, process concept or defined technical requirements that need further development. Some have mature methods or SOPs ready for transfer. Others simply need specialist expertise, equipment or additional resource to complement their own in-house team.
At Fleet Bioprocessing, flexible CRO support means being able to work across that spectrum.
For Fleet, being research led means allowing the science to shape the route rather than starting from a fixed workflow. As the evidence develops, we can refine the approach with the client while keeping the final application and future manufacturability in mind.
Scientific input that reflects the stage of the programme
Different projects require different types and levels of scientific input. Research may mean screening and comparing options at one stage, refining an established technical concept at another or generating the evidence needed to confirm that a process is suitable to progress. One programme may benefit from screening several chemistries, reagents or process conditions before selecting an approach. Another may require refinement of purification, characterisation, formulation or process parameters around an existing technical concept. A more mature programme may need reliable transfer, execution and documentation of an established method.
The development model does not have to be the same for every project.
Designing around the end application
Understanding how the final product will be used can influence decisions made much earlier in development. This is particularly clear in bioconjugation, where the intended application may influence the choice of label or conjugation chemistry, incorporation level, purification strategy, formulation, characterisation and final presentation.
The same principle applies within assay development. The choice and optimisation of reagents needs to be considered alongside the wider assay design, including antibody pairing, conjugate format, assay architecture, sample matrix, sensitivity requirements, stability and intended use.
Rather than assuming that one reagent configuration or conjugation condition will be optimal, it may be appropriate to prepare and evaluate several variants within the assay itself. Performance data can then help determine which reagent and process conditions should be taken forward.
Even where assay development follows a more structured pathway or formal design controls, those controls provide the framework rather than the scientific answer. Development still requires interpretation of the data and decisions about when to refine, repeat or change course.
Bioconjugation and assay development sit at the heart of Fleet. Bringing both together in one CRO supports collaborative, data led development with assay performance, robustness and future manufacturability in mind.
Characterisation and QC built around the questions that matter
A fixed analytical package will not necessarily answer the right questions for every product.
Depending on the material and its intended use, a project might require assessment of purity, aggregation, incorporation, activity, identity or stability, amongst other product specific attributes.
Fleet can draw on a range of analytical approaches, including chromatographic techniques such as size exclusion, affinity, ion exchange and hydrophobic interaction chromatography, alongside spectroscopic, electrophoretic, immunoassay based and other physicochemical methods.
Methods can be transferred from the client, selected from established Fleet approaches, supplemented with additional testing or developed specifically for the programme.
The objective is not to apply every technique available. It is to select the characterisation and QC strategy that answers the relevant questions for that product.
Flexibility in quantity, format and scale
The technical choices do not stop once the core development work is complete.
Clients can have very different requirements for purification, formulation, buffer composition, dispense volume, final presentation, storage format and quantity. Some projects may require a small number of development samples or variants; others progress into larger batches or repeated manufacture.
Fleet can work with an existing client formulation or help develop one, support different dispensing requirements and provide liquid or lyophilised presentation. An established lyophilisation process can be transferred, or a suitable cycle developed where one does not already exist.
The same principle applies to purification and other downstream activities: the approach can be selected around the characteristics of the material and the quantity required rather than being tied to one standard process.
Scale matters too. We can support the space between in house capability and large scale outsourcing, providing specialist expertise, equipment and resource for projects that may only require modest quantities or a focused development programme.
This can be particularly useful when a project has progressed beyond what is practical to carry out internally, but does not require the volumes or infrastructure associated with a large manufacturing campaign.
Working alongside your team
Sometimes the requirement is a complete development programme. In other cases, the client already has substantial in house capability and needs support with a particular activity, additional laboratory resource, specialist expertise or access to equipment they do not have internally.
Fleet can work alongside an existing R&D team rather than requiring the whole programme to be transferred.
That might mean developing and supplying a specialist reagent for an assay being developed internally, undertaking a specific characterisation study, helping address a purification or formulation challenge or carrying out an established process when internal resource is constrained.
That flexibility also applies to how projects get started and progress. Streamlined scoping and quoting, efficient onboarding and responsive scheduling can support shorter lead times and faster project starts than may be practical within larger scale CRO models.
Putting the Research back into CRO
Putting the Research back into CRO means providing more than a predefined workflow. It means using scientific judgement, collaboration and flexibility to shape the right approach for each programme, with robustness, reproducibility, manufacturability and the intended outcome considered throughout.
Discuss your project
Have a project that could benefit from a more flexible scientific approach?
Contact our scientific team to discuss your technical requirements and how Fleet could support your programme.
